• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Accuray Announces First SRS/SBRT Patient Treatments in Austria With the CyberKnife® System

    5/5/25 4:10:00 PM ET
    $ARAY
    Medical/Dental Instruments
    Health Care
    Get the next $ARAY alert in real time by email

    Medical Team's Use of Accuray CyberComm™ Reduced Commissioning Time by Approximately 50 Percent*, Enabling Them to Initiate Patient Treatments Sooner

    MADISON, Wis., May 5, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY) announced today that the CyberKnife® Center Salzburg is the first in Austria to treat patients with the CyberKnife® System, expanding access to stereotactic radiosurgery (SRS) and ultra-hypofractionated stereotactic body radiation therapy (SBRT), treatment processes necessitating an extremely high degree of precision and accuracy. The CyberKnife Center Salzburg's team used the Accuray CyberComm™ technology to commission their system, the latest-generation CyberKnife S7™ System, making it possible for them to more quickly begin treating patients.

    Accuray Incorporated (PRNewsFoto/Accuray Incorporated) (PRNewsFoto/Accuray Incorporated)

    The CyberKnife System facilitates ultra-hypofractionated radiation therapy – very high doses of precisely targeted radiation are delivered in a few days versus conventional fractionation where treatments often require 30-40 sessions. The entire procedure is typically completed in just one to five out-patient sessions, providing access to radiation therapy delivered with sub-millimeter accuracy for people who are unable to travel a month or more for care.

    "Growing evidence demonstrates that for some indications, ultra-hypofractionation is a proven treatment modality that delivers clinical outcomes as good as conventional fractionation while dramatically reducing the number of treatments and lowering the total cost of care. This data is driving increased adoption of hypofractionated – and ultra-hypofractionated treatments as the standard of care. With this shift we're seeing more clinicians choose the CyberKnife® System, which gives them the confidence they need to deliver efficient, yet effective, treatments to their patients," said Seth Blacksburg, M.D., MBA, Chief Medical Officer at Accuray.

    "Radiation therapy represents an essential treatment option at each stage of the cancer journey, that's why we're committed to providing our customers with the resources they need to get the best possible outcomes with our products," said Suzanne Winter, president and CEO of Accuray. "We look forward to working with the CyberKnife® Center Salzburg team as they pave the way for improving cancer care. The CyberKnife S7 System is an extremely versatile and precise radiation delivery system, supporting treatment of an expanded range of indications and giving more patients the chance to experience moments that matter."

    Estimates suggest the number of cancer cases in Austria will increase by almost 25 percent between 2022 and 20401. A European Cancer Inequalities Registry report indicates Austria gets high marks for reimbursement of oncology medications, though the country's supply of radiotherapy equipment is 27 percent lower than the European Union average and 34 percent lower than economic peers2. While there has been a positive trend since 2012 to address this, continued installation of devices like the CyberKnife System will be key to closing the gap.

    "After many years of treating patients as a radiation oncologist in Germany, it was my mission to bring the CyberKnife System to my home country of Austria. From my perspective if the patient has an appropriate indication for high-dose radiotherapy, the system is the device of choice," said Dr. med. univ. Alfred Haidenberger, CyberKnife® Center Salzburg. "The CyberKnife System represents a significant advancement in cancer care and will enable patients to undergo highly precise and effective treatment typically in just a few days, avoiding the weeks of daily sessions often required with conventional radiotherapy. These factors have a major impact on the patient's quality of life."

    Click here to hear from Dr. med. univ. Alfred Haidenberger about the CyberKnife® System.

    *When compared to traditional CyberKnife® System commissioning process.

    Important Safety Information

    For Important Safety Information please refer to https://www.accuray.com/safety-statement.

    About Accuray

    Accuray is committed to expanding the powerful potential of radiation therapy to improve as many lives as possible. We invent unique, market-changing solutions that are designed to deliver radiation treatments for even the most complex cases—while making commonly treatable cases even easier—to meet the full spectrum of patient needs. We are dedicated to continuous innovation in radiation therapy for oncology, neuro-radiosurgery, and beyond, as we partner with clinicians and administrators, empowering them to help patients get back to their lives, faster. Accuray is headquartered in Madison, Wisconsin, with facilities worldwide. To learn more, visit www.accuray.com or follow us on Facebook, LinkedIn, X, and YouTube.

    Safe Harbor Statement

    Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited, to expectations regarding radiation therapy and ultra-hypofractionation, expectations regarding the company's products, clinical applications, clinical results, patient experiences and patient outcomes. These forward-looking statements involve risks and uncertainties. If any of these risks or uncertainties materialize, or if any of the company's assumptions prove incorrect, actual results could differ materially from the results expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, the company's ability to achieve widespread market acceptance of its products, including new product innovations and releases; the company's ability to develop new products or improve existing products to meet customers' needs; the company's ability to anticipate or keep pace with changes in the marketplace; and the direction of technological innovation and customer demands and such other risks identified under the heading "Risk Factors" in the company's Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission (the "SEC") on November 6, 2024, and as updated periodically with the company's other filings with the SEC.

    Forward-looking statements speak only as of the date the statements are made and are based on information available to the company at the time those statements are made and/or management's good faith belief as of that time with respect to future events. The company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not put undue reliance on any forward-looking statements.

    Media Contact:

    Beth Kaplan

    Public Relations Director, Accuray

    +1 (408) 789-4426

    [email protected]

    1 European Cancer Information System (ECIS) of the Joint Research Centre. European Cancer Inequalities Registry. Country Cancer Profile. Accessed March 4, 2025. https://www.oecd.org/content/dam/oecd/en/publications/reports/2025/02/eu-country-cancer-profile-austria-2025_8dd11c12/c8d574cc-en.pdf

    2
    Ibid.

    Accuray CyberKnife S7 System

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/accuray-announces-first-srssbrt-patient-treatments-in-austria-with-the-cyberknife-system-302445766.html

    SOURCE Accuray Incorporated

    Get the next $ARAY alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ARAY

    DatePrice TargetRatingAnalyst
    2/13/2024$9.00Buy
    ROTH MKM
    6/23/2022$7.50Buy
    B. Riley Securities
    12/22/2021$7.50Buy
    Loop Capital
    More analyst ratings

    $ARAY
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Accuray to Participate in the Jefferies Global Healthcare Conference 2025

      MADISON, Wis., May 29, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY) announced today its participation in the Jefferies Global Healthcare Conference 2025. The management team is scheduled to participate in a fireside chat on Wednesday, June 4th, 2025, at 5:30pm EDT/2:30pm PDT. A live webcast of the call will also be available from the Investor Relations section of the company's website at investors.accuray.com. A webcast replay can be accessed on the website and will remain available for 90 days. About AccurayAccuray is committed to expanding the powerful potential o

      5/29/25 7:30:00 PM ET
      $ARAY
      Medical/Dental Instruments
      Health Care
    • Accuray Showcases New Long-Term Data¹ on Benefits of 5 Session Radiotherapy Treatment for Men with Prostate Cancer at ESTRO 2025

      More than 40 Clinical Studies Using Accuray Technology Presented at ESTRO 2025; Company Highlights Innovation and Educational Symposia MADISON, Wis., May 7, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY) announced today that new data presented at the European Society for Radiotherapy and Oncology (ESTRO) meeting reinforces the benefits of the company's CyberKnife® System in the treatment of prostate cancer at multiple stages of the cancer journey. The studies, shared at the annual congress held in Vienna, Austria, indicate the system's accuracy and precision enable treatment of high-risk disease, as well as recurrent prostate cancer following prostatectomy, with stereotactic body r

      5/7/25 7:35:00 AM ET
      $ARAY
      Medical/Dental Instruments
      Health Care
    • Accuray Announces First SRS/SBRT Patient Treatments in Austria With the CyberKnife® System

      Medical Team's Use of Accuray CyberComm™ Reduced Commissioning Time by Approximately 50 Percent*, Enabling Them to Initiate Patient Treatments Sooner MADISON, Wis., May 5, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY) announced today that the CyberKnife® Center Salzburg is the first in Austria to treat patients with the CyberKnife® System, expanding access to stereotactic radiosurgery (SRS) and ultra-hypofractionated stereotactic body radiation therapy (SBRT), treatment processes necessitating an extremely high degree of precision and accuracy. The CyberKnife Center Salzburg's team used the Accuray CyberComm™ technology to commission their system, the latest-generation CyberKnife S

      5/5/25 4:10:00 PM ET
      $ARAY
      Medical/Dental Instruments
      Health Care

    $ARAY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by SVP, Chief Operations Officer Peralta Leonel

      4 - ACCURAY INC (0001138723) (Issuer)

      3/3/25 5:41:56 PM ET
      $ARAY
      Medical/Dental Instruments
      Health Care
    • SEC Form 3 filed by new insider Peralta Leonel

      3 - ACCURAY INC (0001138723) (Issuer)

      2/13/25 4:10:11 PM ET
      $ARAY
      Medical/Dental Instruments
      Health Care
    • SVP Chief Financial Officer Pervaiz Ali covered exercise/tax liability with 2,013 shares, decreasing direct ownership by 0.55% to 362,231 units (SEC Form 4)

      4 - ACCURAY INC (0001138723) (Issuer)

      1/2/25 5:32:36 PM ET
      $ARAY
      Medical/Dental Instruments
      Health Care

    $ARAY
    Financials

    Live finance-specific insights

    See more
    • Accuray Reports Fiscal 2025 Third Quarter Financial Results

      MADISON, Wis., April 30, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY) today reported financial results for the third quarter ended March 31, 2025. Key Fiscal Third Quarter Highlights: Total net revenue was $113.2 million, an increase of 12 percent year-over-yearNet loss was $1.3 million compared to a net loss of $6.3 million in the prior year periodAdjusted EBITDA was $6.0 million compared to $1.1 million in the prior year period"We achieved a strong third quarter and I am proud of the resiliency of the entire team and their focus on driving actions to mitigate the

      4/30/25 4:05:00 PM ET
      $ARAY
      Medical/Dental Instruments
      Health Care
    • Accuray to Report Third Quarter Fiscal 2025 Financial Results on April 30, 2025

      MADISON, Wis., April 16, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY) will report financial results for the third quarter of fiscal year 2025, ended March 31, 2025, during a conference call hosted by company management at 1:30 p.m. PT/4:30 p.m. ET on April 30, 2025. The conference call dial-in numbers are 1-833-316-0563 (USA) or 1-412-317-5747 (international). In addition, a dial-up replay of the conference call will be available approximately one hour after the call's conclusion for one week. The replay number is 1-877-344-7529 (USA) or 1-412-317-0088 (internationa

      4/16/25 4:05:00 PM ET
      $ARAY
      Medical/Dental Instruments
      Health Care
    • Accuray Reports Strong Fiscal 2025 Second Quarter Financial Results & Raises Guidance

      MADISON, Wis., Feb. 5, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY) today reported financial results for the second quarter ended December 31, 2024. Key Fiscal Q2 Highlights: Strong second quarter and first half results; raising fiscal year 2025 guidanceTotal net revenue was $116.2 million, an increase of 8 percent year-over-yearNet income was $2.5 million compared to a net loss of $9.6 million in the prior year periodAdjusted EBITDA was $9.6 million compared to $2.0 million in the prior year period"Our strong Q2 performance reflects outstanding execution of our str

      2/5/25 4:05:00 PM ET
      $ARAY
      Medical/Dental Instruments
      Health Care

    $ARAY
    Leadership Updates

    Live Leadership Updates

    See more
    • Leonel Peralta to Join Accuray as Chief Operations Officer

      MADISON, Wis., Jan. 21, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY) announced today that Leonel Peralta is joining the company as Senior Vice President, Chief Operations Officer, effective February 3, 2025. Mr. Peralta will be responsible for leading worldwide manufacturing operations including driving alignment of operations with corporate business goals, maximizing supply chain profitability and efficiency, and ensuring processes support best-in-class customer service. He will report to Accuray President and Chief Executive Officer Suzanne Winter. Mr. Peralta has

      1/21/25 9:15:00 AM ET
      $ARAY
      Medical/Dental Instruments
      Health Care
    • Accuray Appoints Michael Murphy as VP, Corporate Controller

      MADISON, Wis., Oct. 21, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY) announced today that Michael Murphy, CPA has joined the company as Vice President, Corporate Controller. Mr. Murphy will be responsible for leading the global accounting function including corporate tax, regulatory reporting, accounting policies, and risk management, along with associated budgetary and administrative operations. He will report to Accuray Senior Vice President & Chief Financial Officer Ali Pervaiz. The company also expects to appoint Mr. Murphy to the position of principal accounting officer following the filing of the company's quarterly report on Form 10-Q for the period ended September 30, 2024

      10/21/24 4:05:00 PM ET
      $ARAY
      Medical/Dental Instruments
      Health Care
    • Robert C. Kill Joins Accuray Board of Directors

      SUNNYVALE, Calif., Feb. 1, 2023 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY) announced today the appointment of Robert C. Kill to the company's Board of Directors, effective as of January 30, 2023. Mr. Kill is a skilled healthcare executive with more than 30 years' experience transforming various healthcare-related companies. In his most recent executive position as CEO of Parata Systems, Mr. Kill grew company revenue over 5X during his tenure before it sold last year for more than $1.5 billion. Before Parata, Mr. Kill was affiliated with two private equity funds, Frazie

      2/1/23 4:10:00 PM ET
      $ARAY
      Medical/Dental Instruments
      Health Care

    $ARAY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • ROTH MKM initiated coverage on Accuray with a new price target

      ROTH MKM initiated coverage of Accuray with a rating of Buy and set a new price target of $9.00

      2/13/24 6:29:42 AM ET
      $ARAY
      Medical/Dental Instruments
      Health Care
    • B. Riley Securities initiated coverage on Accuray with a new price target

      B. Riley Securities initiated coverage of Accuray with a rating of Buy and set a new price target of $7.50

      6/23/22 7:25:39 AM ET
      $ARAY
      Medical/Dental Instruments
      Health Care
    • Loop Capital initiated coverage on Accuray with a new price target

      Loop Capital initiated coverage of Accuray with a rating of Buy and set a new price target of $7.50

      12/22/21 4:56:14 AM ET
      $ARAY
      Medical/Dental Instruments
      Health Care

    $ARAY
    SEC Filings

    See more
    • SEC Form SD filed by Accuray Incorporated

      SD - ACCURAY INC (0001138723) (Filer)

      5/30/25 4:01:08 PM ET
      $ARAY
      Medical/Dental Instruments
      Health Care
    • SEC Form 10-Q filed by Accuray Incorporated

      10-Q - ACCURAY INC (0001138723) (Filer)

      5/2/25 4:05:24 PM ET
      $ARAY
      Medical/Dental Instruments
      Health Care
    • Accuray Incorporated filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - ACCURAY INC (0001138723) (Filer)

      4/30/25 4:10:13 PM ET
      $ARAY
      Medical/Dental Instruments
      Health Care

    $ARAY
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Whitters Joseph E bought $156,045 worth of shares (100,000 units at $1.56), increasing direct ownership by 22% to 561,053 units (SEC Form 4)

      4 - ACCURAY INC (0001138723) (Issuer)

      5/30/24 4:10:11 PM ET
      $ARAY
      Medical/Dental Instruments
      Health Care

    $ARAY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Accuray Incorporated

      SC 13G/A - ACCURAY INC (0001138723) (Subject)

      9/6/24 9:00:07 AM ET
      $ARAY
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by Accuray Incorporated

      SC 13G - ACCURAY INC (0001138723) (Subject)

      2/13/24 4:56:01 PM ET
      $ARAY
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by Accuray Incorporated (Amendment)

      SC 13G/A - ACCURAY INC (0001138723) (Subject)

      2/13/24 11:19:22 AM ET
      $ARAY
      Medical/Dental Instruments
      Health Care